ADMA Biologics GAAP EPS of $0.20 beats by $0.02, revenue of $139.16M misses by $0.64M
Source: SeekingAlpha
2026-02-25 16:29:20 ET
More on ADMA Biologics
- ADMA Biologics: Business Update And My Price Target
- ADMA Biologics, Inc. (ADMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- The Play On ADMA Biologics: A Discounted Stock With Good Prospects
- ADMA Biologics reports FY 2025 revenue in line with estimate, provides 2026–2029 outlook
- Seeking Alpha’s Quant Rating on ADMA Biologics
Read the full article on Seeking Alpha
For further details see:
ADMA Biologics GAAP EPS of $0.20 beats by $0.02, revenue of $139.16M misses by $0.64M
ADMA Biologics Inc
NASDAQ: ADMA
ADMA Trading
-2.15% G/L:
$15.68 Last:
620,712 Volume:
$15.76 Open:
ADMA Latest News
March 02, 2026 07:00:00 am
ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative
February 25, 2026 04:05:00 pm
ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 18, 2026 07:00:00 am
ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
ADMA Stock Data
$3,926,963,123
229,191,848
0.3%
148
N/A
Biotechnology & Life Sciences
Healthcare
US
Ramsey
